Since the onset of the coronavirus disease 2019 (COVID-19) pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), over 6.38 million deaths and 572 million infections have ...

The coronavirus disease 2019 (COVID-19) pandemic was caused by the rapid spread of coronavirus disease-2 (SARS-CoV-2). To date, this pandemic has claimed more than 5.77 million lives worldwide.

The efficacy of Merck’s COVID-19 antiviral has fallen sharply. While most Americans were sleeping off Thanksgiving, Merck revealed the relative risk reduction fell from 50% to 30% in the final ...

Credit: Getty Images. The phase 3 MOVe-OUT trial included all 1433 at risk adults with mild to moderate COVID-19 and symptom onset within 5 days of randomization. Final analysis from the phase 3 ...

SARS-CoV-2 variants of concern and the biological sex of patients affect the efficacy of molnupiravir, the first orally available drug approved for outpatient use against COVID-19, according to a new ...

This article is part of a larger series on the risks of molnupiravir. For a summary of the risks at the level of the individual, see here, and for an overview of the risks on a societal level, see ...

(RTTNews) - Merck (MRK) and Ridgeback Biotherapeutics issued an update on the MOVe-OUT study of molnupiravir, an investigational oral antiviral medicine for COVID-19. In the study, Molnupiravir ...

The US Food and Drug Administration (FDA) has issued emergency use authorization to a second oral COVID-19 treatment. Called molnupiravir the new drug is not as effective as Pfizer’s recently approved ...

Ahead of a U.S Food and Drug Administration advisory panel meeting, drugmaker Merck has revealed final analysis data from a Phase 3 trial testing its oral antiviral pill against COVID-19. The new data ...

KENILWORTH, N.J. & MIAMI--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics today announced that Japan’s Ministry of Health, Labor ...

Credit: Merck. The EUA was supported by data from the phase 3 MOVe-OUT trial, which compared the efficacy and safety of molnupiravir to placebo in 775 nonhospitalized adults with symptom onset within ...